AbbVie Announces Reimbursement For VRAYLAR For Treatment Of Schizophrenia Under Non-Insured Health Benefits (NIHB) Program
Portfolio Pulse from Benzinga Newsdesk
AbbVie has announced that its schizophrenia treatment drug, VRAYLAR, will be reimbursed under the Non-Insured Health Benefits (NIHB) Program. This will make the drug more accessible to patients in need.
June 07, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's VRAYLAR will be reimbursed under the NIHB Program, potentially increasing the drug's sales and revenue for the company.
The reimbursement of VRAYLAR under the NIHB Program will make the drug more accessible to patients, which could lead to increased sales and revenue for AbbVie. As the drug is directly related to the company's product portfolio, this news is highly relevant and important for investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100